================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
AND EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
AND EXCHANGE ACT OF 1934
For the transition period from ______________________ to ____________________
Commission file number 0-28150
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 33-0525145
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
10555 SCIENCE CENTER DRIVE
SAN DIEGO, CALIFORNIA 92121
(Address of principal executive offices)
(858) 658-7600
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:
Yes X No
The number of outstanding shares of the registrant's common stock, par
value of $0.001, was 22,066,248 as of October 31, 2000.
================================================================================
<PAGE>
NEUROCRINE BIOSCIENCES, INC.
FORM 10-Q INDEX
PAGE
PART I. FINANCIAL INFORMATION
ITEM 1: Financial Statements............................................ 3
Condensed Balance Sheets as of September 30, 2000
and December 31, 1999...................................... 3
Condensed Statements of Operations for the three and
nine months ended September 30, 2000 and 1999.............. 4
Condensed Statements of Cash Flows for nine months
ended September 30, 2000 and 1999.......................... 5
Notes to the Condensed Financial Statements..................... 6
ITEM 2: Management's Discussion and Analysis of
Financial Condition and Results of Operations.............. 7
ITEM 3: Quantitative and Qualitative Disclosures About Market Risk...... 11
PART II. OTHER INFORMATION
ITEM 6: Exhibits and Reports on Form 8-K................................ 11
SIGNATURES................................................. 12
Page 2
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
NEUROCRINE BIOSCIENCES, INC.
CONDENSED BALANCE SHEETS
(in thousands)
Sep 30, Dec 31,
2000 1999
--------- ---------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents ........................ $ 11,163 $ 21,265
Short-term investments, available-for-sale ....... 68,285 69,833
Receivables under collaborative agreements ....... 1,265 1,458
Other current assets ............................. 1,905 2,257
--------- ---------
Total current assets ........................... 82,618 94,813
Property and equipment, net ...................... 11,166 11,181
Other assets ..................................... 2,476 3,228
--------- ---------
Total assets ................................... $ 96,260 $ 109,222
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ................................. $ 783 $ 2,447
Accrued liabilities .............................. 8,399 5,069
Deferred revenues ................................ 48 155
Current portion of long-term debt ................ 149 149
Current portion of capital lease obligations ..... 998 825
--------- ---------
Total current liabilities ...................... 10,377 8,645
Long-term debt ................................... 199 312
Capital lease obligations ........................ 1,711 1,827
Deferred rent .................................... 1,500 1,005
Other liabilities ................................ 1,038 1,079
--------- ---------
Total liabilities .............................. 14,825 12,868
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares
authorized; no shares issued and outstanding ... -- --
Common stock, $0.001 par value; 50,000,000 shares
authorized; issued and outstanding shares were
22,062,437 in 2000 and 21,608,011 in 1999 ...... 22 22
Additional paid in capital ....................... 142,798 138,798
Deferred compensation and shareholder notes ...... (162) (530)
Accumulated other comprehensive loss ............. (177) (264)
Accumulated deficit .............................. (61,046) (41,672)
--------- ---------
Total stockholders' equity ..................... 81,435 96,354
--------- ---------
Total liabilities and stockholders' equity ..... $ 96,260 $ 109,222
========= =========
See accompanying notes to the condensed financial statements.
Page 3
<PAGE>
NEUROCRINE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF OPERATIONS
(unaudited; in thousands except loss per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------ ------------------
2000 1999 2000 1999
-------- -------- -------- --------
Revenues:
Sponsored research and development .. $ 1,887 $ 4,209 $ 4,943 $ 9,760
Sponsored research and development
from related party -- -- -- 501
License and option fees ............. 3,050 -- 5,050 --
Milestones .......................... -- 750 -- 1,500
Grant income and other revenues ..... 386 272 1,050 831
-------- -------- -------- --------
Total revenues 5,323 5,231 11,043 12,592
Operating expenses:
Research and development ............ 12,499 8,331 28,404 21,893
General and administrative .......... 2,509 1,882 6,930 5,587
-------- -------- -------- --------
Total operating expenses ......... 15,008 10,213 35,334 27,480
Loss from operations ................. (9,685) (4,982) (24,291) (14,888)
Other income and (expenses):
Interest income ..................... 1,431 623 4,466 2,209
Interest expense .................... (61) (59) (173) (169)
Other income and expenses, net ...... 282 11 926 (285)
-------- -------- -------- --------
Loss before income taxes ............. (8,033) (4,407) (19,072) (13,133)
Income taxes ......................... 102 -- 302 --
-------- -------- -------- --------
Net loss ............................. $ (8,135) $ (4,407) $(19,374) $(13,133)
======== ======== ======== ========
Loss per common share:
Basic and diluted .................. $ (0.37) $ (0.23) $ (0.88) $ (0.69)
Shares used in the calculation
of loss per common share:
Basic and diluted .................. 22,032 19,006 21,900 18,975
See accompanying notes to condensed financial statements.
Page 4
<PAGE>
NEUROCRINE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited; in thousands)
Nine Months Ended
September 30,
--------------------
2000 1999
-------- --------
CASH FLOW FROM OPERATING ACTIVITIES
Net loss ................................................ $(19,374) $(13,133)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Equity in NPI losses and other adjustments ........ -- 1,175
Depreciation and amortization ..................... 1,618 1,532
Deferred revenues ................................. (107) 567
Deferred expenses ................................. 785 1,008
Non-cash stock compensation expenses .............. 1,986 252
Change in operating assets and liabilities:
Accounts receivable and other current assets . 545 (2,732)
Other non-current assets ..................... 837 124
Accounts payable and accrued liabilities ..... 886 (1,215)
-------- --------
Net cash flows used in operating activities (12,824) (12,422)
CASH FLOW FROM INVESTING ACTIVITIES
Purchases of short-term investments ..................... (25,140) (26,763)
Sales/maturities of short-term investments .............. 26,775 36,637
Purchases of property and equipment ..................... (1,688) (1,990)
-------- --------
Net cash flows (used in) provided by investing activities (53) 7,884
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock .................. 2,816 358
Proceeds from capital lease financing ................... 650 771
Principal payments on long-term obligations ............. (706) (708)
Principal payments received on notes from stockholders .. 15 --
-------- --------
Net cash flows provided by financing activities ......... 2,775 421
-------- --------
Net decrease in cash and cash equivalents ............... (10,102) (4,117)
Cash and cash equivalents at beginning of the period .... 21,265 11,708
-------- --------
Cash and cash equivalents at end of the period .......... $ 11,163 $ 7,591
======== ========
See accompanying notes to the condensed financial statements.
Page 5
<PAGE>
NEUROCRINE BIOSCIENCES, INC.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
1. ORGANIZATION
Neurocrine Biosciences, Inc. ("we", "Neurocrine" or the "Company") was
incorporated in California on January 17, 1992 and was reincorporated in
Delaware in March 1996. In May 1998, we acquired Northwest NeuroLogic, Inc.
("NNL"), an Oregon-based research corporation. In December 1999, the NNL
corporate structure was merged with and into the Company. Between March 1996 and
December 1999, we owned a minority interest in Neuroscience Pharma, Inc.
("NPI"), a Canadian based research and development company.
Neurocrine is a product-focused biopharmaceutical company focused on
neurologic and endocrine diseases and disorders. Our product candidates address
on some of the largest pharmaceutical markets in the world including insomnia,
anxiety, depression, cancer and diabetes. Although we currently have no marketed
products, we have 15 drug candidate programs in various stages of research and
development. We are collaborating on four of these programs with Janssen
Pharmaceutica, a subsidiary of Johnson & Johnson, Wyeth-Ayerst, Taisho
Pharmaceuticals ("Taisho") and Eli Lilly ("Lilly").
2. BASIS OF PRESENTATION
The condensed financial statements included herein are unaudited. Current
year financial statements consist of our accounts, including those activities of
our Oregon based facility currently operating under our name. Prior year
financial statements include the consolidation of our accounts - and those of
our Oregon based facility, formerly known as NNL. All significant inter-company
transactions were eliminated in consolidation. Our minority ownership interest
in NPI was accounted for under the equity method. Certain reclassifications have
been made to prior year amounts to conform to the presentation for the three and
nine months ended September 30, 2000.
The condensed financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information and
with the instructions of the Securities and Exchange Commission ("SEC") on Form
10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of
the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management,
these financial statements include all adjustments (consisting of normal
recurring adjustments) necessary for a fair presentation of the financial
position, results of operations, and cash flows for the periods presented.
The results of operations for the interim periods shown in this report are
not necessarily indicative of results expected for the full year. The financial
statements should be read in conjunction with the audited financial statements
and notes for the year ended December 31, 1999, included in our Annual Report on
Form 10-K filed with the Securities and Exchange Commission.
3. USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the period. Actual results could differ from those estimates.
4. LOSS PER COMMON SHARE
Basic net loss per common share is calculated using the weighted
average number of common shares outstanding during the period. Diluted net loss
per common share is calculated by adding the total incremental number of common
share equivalents and the weighted average number of common shares outstanding
during the period. For the periods presented, incremental shares of the common
share equivalents were excluded from the calculation of diluted net loss per
share as their effects were antidilutive.
Page 6
<PAGE>
5. COMPREHENSIVE INCOME
Our comprehensive losses consist of net losses and unrealized gains and
losses on investments. The accumulated balances of these components are
disclosed as a separate component of stockholders' equity.
6. NEW ACCOUNTING PRONOUNCEMENTS
In December 1999, the SEC issued Staff Accounting Bulletin No. 101 ("SAB
101"), "Revenue Recognition in Financial Statements". SAB 101 provides guidance
in applying generally accepted accounting principles to revenue recognition in
financial statements, including the recognition of nonrefundable up-front fees
received in conjunction with a research and development arrangement. We are
required to adopt the pronouncement during the fourth quarter of 2000. During
the current quarter, we received a $3.0 million license fee pursuant to our
agreement with Taisho. Upon adoption of SAB 101, this fee may be deferred and
recognized as income ratably over five years, the expected life of the
agreement. Aside from this transaction, management does not expect SAB 101 to
have a material effect on revenues recognized in prior periods.
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following Management's Discussion and Analysis of Financial Condition
and Results of Operations of the Company contain forward-looking statements
which involve risks and uncertainties, pertaining generally to the expected
continuation of our collaborative agreements, the receipt of research payments
thereunder, the future achievement of various milestones in product development
and the receipt of payments related thereto, the potential receipt of royalty
payments, pre-clinical testing and clinical trials of potential products, the
period of time our existing capital resources will meet our funding
requirements, and financial results and operations. Actual results could differ
materially from those anticipated in these forward-looking statements as a
result of various factors, including those set forth below and those outlined in
our 1999 Annual Report on Form 10-K and the most recent Form S-3 filed with the
SEC.
OVERVIEW
We incorporatedin California in 1992 and reincorporated in Delaware in
1996. Since we were founded, we have been engaged in the discovery and
development of novel pharmaceutical products for diseases and disorders of the
central nervous and endocrine systems. To date, we have not generated any
revenues from the sale of products, and do not expect to generate any product
revenues in the foreseeable future. We have funded our operations primarily
through private and public offerings of our common stock and payments under
research and development agreements. We are developing a number of products with
corporate collaborators and will rely on existing and future collaborators to
meet funding requirements. We expect to generate future net losses in
anticipation of increases in operating expenses as products are advanced through
the various stages of clinical development. As of September 30, 2000, we have
incurred a cumulative deficit of $61.0 million and expect to incur operating
losses in the future, which may be greater than losses in prior years.
Page 7
<PAGE>
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 2000 AND 1999
Revenues for the third quarter of 2000 were $5.3 million compared with $5.2
million for the same period last year. In July 2000, we signed a collaborative
agreement with Taisho for the exclusive rights to NBI-6024, our altered peptide
ligand for diabetes, in Europe and Asia. Under that agreement, we recorded a
$3.0 million license fee and $388,000 in sponsored development revenues from
Taisho. The increase in revenues provided by the Taisho and exising
collaborations were partially off set by the absence of revenues received under
collaborations, which concluded during late 1999 and early 2000. The sponsored
research portion of the Lilly agreement was concluded in October 1999 and the
collaboration with Novartis was concluded in January 2000. Under the Novartis
and Lilly agreements, we received $1.7 million in sponsored research and
development revenues. In the third quarter of 1999, we also received a $750,000
milestone payment from Wyeth-Ayerst, and $1.7 million in revenues under the
Janssen agreement for research performed during April through August 1999.
Research and development expenses increased to $12.5 million for the third
quarter 2000 compared with $8.3 million for the respective period in 1999. The
increase in expenses primarily reflects higher costs associated with expanding
clinical development activities and the addition of scientific personnel. Also
included in the expenses for the third quarter 2000 were $401,000 of non-cash
charges associated with the employee stock purchase program and options granted
to consultants, compared to $74,000 in the respective quarter in 1999.
General and administrative expenses increased to $2.5 million for the third
quarter 2000 compared with $1.9 million for the same period last year. This
increase resulted primarily from business development consulting expenses and
non-cash charges associated with the employee stock purchase program and options
granted to consultants. In the third quarters of 2000 and 1999, business
development consulting expense was $328,000 and $2,000, respectively and
non-cash charges associated with the employee stock purchase program and options
granted to consultants were $264,000 and $56,000, respectively.
Interest income increased to $1.4 million during the third quarter of 2000
compared to $623,000 for the same period last year. The increase was primarily
due to higher investment balances generated by our private placement of our
common stock in December 1999. This transaction generated net proceeds of $39.3
million.
Net loss for the third quarter of 2000 was $8.1 million, or $0.37 per share,
compared to $4.4 million, or $0.23 per share, for the same period in 1999. The
increase in net loss resulted from an increase in operating expenses of $4.8
million, partially off set by an increase in revenues of $92,000 and in interest
income of $808,000. Net losses are expected to increase this year due to higher
operating costs associated with the advancement of our compounds through
progressive clinical development, the addition of scientific personnel and legal
expenses relating to patent filing and litigation.
NINE MONTHS ENDED SEPTEMBER 30, 2000 AND 1999
Revenues for the nine months ended September 30, 2000 were $11.0 million
compared with $12.6 million in the same period in 1999. Although we recorded
$5.4 million under the Taisho relationship during the first nine months of 2000,
this increase in revenues was off set by the conclusion of the Novartis
collaboration in January 2000 and a portion of the Lilly collaboration in
October 1999. Under the Novartis and Lilly agreements, we received sponsored
research and development revenues in 1999, which did not recur in 2000. We also
received $1.5 million in milestone payments from Wyeth-Ayerst during 1999.
During the third quarter of 2000, we received a $3.0 million license fee
from Taisho, which was recognized as income. In the fourth quarter 2000, we are
required to adopt SAB 101 issued by the SEC. This pronouncement provides
guidance on the recognition of up-front payments received under research and
development agreements. Under the pronouncement, the $3.0 million license fee
will be deferred and recognized as income over the life of the Taisho agreement,
estimated at 5 years.
For the nine months ended September 30, 2000 and 1999, research and
development expenses were $28.4 million and $21.9 million, respectively. The
increase in expenses reflects higher costs associated with expanding clinical
development activities and the addition of scientific personnel. Also included
in the nine months ended September 30, 2000, were $1.1 million of non-cash
charges associated with the employee stock purchase program and options granted
to consultants, compared to $118,000 for the same period in 1999. These expenses
are expected to rise over the remainder of 2000 as clinical studies are expanded
on current compounds and new compounds advance to the clinical development
stages.
Page 8
<PAGE>
For the nine months ended September 30, 2000 and 1999, general and
administrative expenses totaled $6.9 million and $5.6 million, respectively.
This increase resulted primarily from business development consulting expenses
and non-cash charges associated with the employee stock purchase program and
options granted to consultants. In the nine months ended September 30, 2000 and
1999, business development consulting expenses were $580,000 and $8,000,
respectively, and non-cash charges associated with the employee stock purchase
program and options granted to consultants were $876,000 and $134,000,
respectively. These expenses are expected to continue to rise over the remainder
of 2000.
Interest income increased to $4.5 million during the nine months ended
September 30, 2000 compared to $2.2 million for the same period last year. The
increase was primarily due to higher investment balances generated by our
private placement of common stock. Completed in December 1999, this transaction
generated net proceeds of $39.3 million. We anticipate interest earnings for the
remainder of the 2000 to decline from quarter-to-quarter as cash reserves are
needed to fund progressive clinical trials and hire additional scientific
personnel.
Net loss for the first nine months of 2000 was $19.4 million, or $0.88 per
share, compared to $13.1 million, or $0.69 per share, for the same period in
1999. The increase in net loss resulted from a decline in revenues of $1.6
million, an increase in operating expenses of $7.9 million and an increase in
Japanese income taxes of $300,000 associated with the Taisho agreement. These
factors were partially off set by an increase in interest income of $2.3
million. During the first nine months of 1999, we recorded equity in NPI losses
of $1.2 million. Net losses are expected to increase this year due to higher
operating costs associated with the advancement of our compounds through
progressive clinical development and the addition of scientific personnel.
To date, our revenues have come from funded research and achievements of
milestones under corporate collaborations. The nature and amount of these
revenues from period-to-period may lead to substantial fluctuations in the
results of quarterly revenues and earnings. Accordingly, results and earnings of
one period are not predictive of future periods.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2000, our cash, cash equivalents, and short-term
investments totaled $79.4 million compared with $91.1 million at December 31,
1999. The decline in cash balances during 2000 reflects the funding of
progressive clinical development programs and the addition of scientific
personnel.
Net cash used in operating activities during the first nine months of 2000
was $12.8 million compared with $12.4 million for the same period last year. The
increase in net cash used resulted primarily from the funding of clinical trials
and the addition of scientific personnel. We expect cash usage to continue
during the fourth quarter as clinical trial efforts are expanded.
Net cash used in investing activities during the first nine months of 2000
was $53,000 compared with net cash provided of $7.9 million during the same
period in 1999. The increase in cash used resulted primarily from the timing
differences in the investment purchases, sales, maturities and the fluctuations
in our portfolio mix between cash equivalents and short-term investment
holdings. We expect similar fluctuations to continue throughout the year.
Net cash provided by financing activities during 2000 was $2.8 million
compared to $421,000 during the same period of 1999. This increase was primarily
the result of proceeds received from stock option exercises and the employee
stock purchase plan.
Page 9
<PAGE>
We believe that our existing capital resources, together with interest
income and future payments due under the strategic alliances, will be sufficient
to satisfy our current and projected funding requirements at least for the next
12 months. However, we face the risk that such capital resources and payments
may not be sufficient to conduct our research and development programs as
planned. The amount and timing of expenditures will vary depending upon a number
of factors, including progress of our research and development programs.
We will require additional funding for the continuation of our research and
product development programs, for progress with preclinical testing and clinical
trials, for operating expenses, for the pursuit of regulatory approvals for our
product candidates, for the costs involved in filing and prosecuting patent
applications and enforcing or defending patent claims, if any, the cost of
product in-licensing and any possible acquisitions, and we may require
additional funding for establishing manufacturing and marketing capabilities in
the future. We may seek to access the public or private equity markets whenever
conditions are favorable. We may also seek additional funding through strategic
alliances and other financing mechanisms, potentially including off-balance
sheet financing. There can be no assurance that adequate funding will be
available on terms acceptable to us, if at all. If adequate funds are not
available, we may be required to curtail significantly one or more of our
research or development programs or obtain funds through arrangements with
collaborative partners or others. This may require us to relinquish rights to
certain of our technologies or product candidates.
We expect to incur operating losses over the next several years as our
research, development, preclinical testing and clinical trial activities
increase. To the extent that we are unable to obtain third party funding for
such expenses, we expect that increased expenses will result in increased losses
from operations. In addition, there can be no assurance that our products will
be successfully developed or that, if successfully developed, will generate
revenues sufficient to enable us to earn a profit.
INTEREST RATE RISK
We are exposed to interest rate risk on our short-term investments and on
our long-term debt. The primary objective of our investment activities is to
preserve principal while at the same time maximizing yields without
significantly increasing risk. To achieve this objective, we invest in highly
liquid and high quality government and other debt securities. To minimize the
exposure due to adverse shifts in interest rates, we invest in short-term
securities with maturities of less than 44 months. If a 10% change in interest
rates were to have occurred on September 30, 2000, such a change would not have
had a material effect on the fair value of our investment portfolio as of that
date. Due to the short holding period of our investments, we have concluded that
we do not have a material financial market risk exposure.
Interest risk exposure on long-term debt relates to our note payable,
which bears a floating interest rate of prime plus one quarter percent (9.50% at
September 30, 2000 and 8.75% at December 31, 1999). At September 30, 2000 and
December 31, 1999, the note balance was $348,000 and $461,000, respectively.
This note is payable in equal monthly installments through January 2003. Based
on the balance of its long-term debt, we have concluded that we do not have a
material financial market risk exposure.
CAUTION ON FORWARD-LOOKING STATEMENTS
Our business is subject to significant risks, including but not limited to,
the risks inherent in our research and development activities, including the
successful continuation of our strategic collaborations, the successful
completion of clinical trials, the lengthy, expensive and uncertain process of
seeking regulatory approvals, uncertainties associated both with the potential
infringement of patents and other intellectual property rights of third parties,
and with obtaining and enforcing our own patents and patent rights,
uncertainties regarding government reforms and of product pricing and
reimbursement levels, technological change and competition, manufacturing
uncertainties and dependence on third parties. Even if our product candidates
appear promising at an early stage of development, they may not reach the market
for numerous reasons. Such reasons include the possibilities that the product
will be ineffective or unsafe during clinical trials, will fail to receive
necessary regulatory approvals, will be difficult to manufacture on a large
scale, will be uneconomical to market or will be precluded from
commercialization by proprietary rights of third parties.
Page 10
<PAGE>
For a further discussion of the risks associated with an investment in
Neurocrine, please see the section entitled "Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 1999 and our most recent Form S-3
filed with the SEC.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
A discussion of our exposure to, and management of, market risk appears in
Part 1, Item 2 of this Quarterly Report on Form 10-Q under the heading "Interest
Rate Risk".
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(A) Exhibits. The following exhibits are filed as part of this report:
27 Financial Data Schedule
(B) Reports on Form 8-K. There were no reports filed on Form 8-K
during the quarter ended September 30, 2000.
Page 11
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: 11/08/00 /s/ Paul W. Hawran
-------- ------------------
Paul W. Hawran
Executive Vice President and
Chief Financial Officer
Page 12
<PAGE>
EXHIBIT INDEX
27 Financial Data Schedule
<PAGE>
